Lemaitre Vascular (LMAT) Research & Development (2010 - 2026)

Lemaitre Vascular (LMAT) has reported Research & Development for 17 consecutive years, with $14.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 3.27% year-over-year to $14.4 million in Q2 2026; TTM through Jun 2026 was $54.3 million, a 2.08% increase from a year earlier, with the FY2025 full-year figure at $54.5 million, up 16.53% from the prior year.
• Research & Development was $14.4 million for Q2 2026 at Lemaitre Vascular, down from $14.5 million in the prior quarter.
• Over five years, Research & Development peaked at $14.9 million in Q2 2025 and troughed at $7.8 million in Q1 2022.
• A 5-year average of $11.3 million and a median of $11.2 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 38.82% in 2023 and retreated 3.27% in 2026, its largest moves.
• Over 5 years, Research & Development stood at $8.6 million in 2022, then grew by 19.4% to $10.3 million in 2023, then grew by 22.96% to $12.6 million in 2024, then advanced by 6.4% to $13.4 million in 2025, then increased by 7.25% to $14.4 million in 2026.
• The last three Research & Development figures came in at $14.4 million (Q2 2026), $14.5 million (Q1 2026), and $13.4 million (Q4 2025), per Business Quant data.